SSY Group (02005) obtained the drug production registration approval from the National Medical Products Administration for injectable Diltiazem Hydrochloride (10mg).
ShiSi Pharmaceutical Group (02005) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for injectable Diltiazem Hydrochloride (10mg), which belongs to class 4 chemical drugs and is considered equivalent through consistency evaluation. Injectable Diltiazem Hydrochloride is mainly used for paroxysmal supraventricular tachycardia, emergency treatment of high blood pressure during surgery, hypertensive emergencies, and unstable angina.
SSY GROUP (02005) announced that the group has obtained the drug production registration approval for the injectable solution of Diltiazem Hydrochloride (10mg) from the China National Medical Products Administration, which belongs to the category 4 of chemical drugs and is considered to have passed the consistency evaluation. Diltiazem Hydrochloride injection is mainly used for supraventricular tachycardia, emergency management of high blood pressure during surgery, hypertensive emergencies, and unstable angina.
The Board of Directors also happily announced that the group has obtained the approval for the injection solution of Propranolol Hydrochloride (5ml: 5mg and 2ml: 2mg) from the National Medical Products Administration, which belongs to the category 3 of chemical drugs and is considered to have passed the consistency evaluation. Propranolol Hydrochloride injection is mainly used for controlling supraventricular and ventricular arrhythmias, effort angina, and pheochromocytoma (used in combination with alpha-adrenergic blockers to control tachycardia). The raw material of Propranolol Hydrochloride of the group has been approved by the National Medical Products Administration for use in marketed formulations.
Related Articles
HK Stock Market Move | SINOPHARM (01099) falls nearly 4% in the afternoon, with first quarter net profit attributable to shareholders dropping nearly 3% year-on-year.
BoC International: Three major technologies advancing together, optimistic about the potential growth space of the brain-machine interface industry.
AI cockpit volume + product going abroad: Guotai Haitong initiates PATEO (02889) with a "buy" rating, target price of HKD 236.98.
HK Stock Market Move | SINOPHARM (01099) falls nearly 4% in the afternoon, with first quarter net profit attributable to shareholders dropping nearly 3% year-on-year.
BoC International: Three major technologies advancing together, optimistic about the potential growth space of the brain-machine interface industry.
AI cockpit volume + product going abroad: Guotai Haitong initiates PATEO (02889) with a "buy" rating, target price of HKD 236.98.
